iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, announces the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi’s capabilities in developing cutting-edge immunotherapies for solid tumors. As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune’s shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc.
Read the full article: iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors //
Source: https://www.prnewswire.com/news-releases/ioncologi-inc-acquires-targimmune-therapeutics-to-expand-and-strengthen-immunotherapy-pipeline-against-solid-tumors-302402307.html